Previous 10 | Next 10 |
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2021 PR Newswire SALT LAKE CITY , May 6, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, to...
April is Getting Off to a Great Start For These 5 Biotech Stocks With only six days behind us in April so far, biotech penny stocks continue to lead the charge. Since they’re so cheap (stocks under $5, by definition), traders are on the hunt for the next breakout name. The obviou...
Gainers: Neos Therapeutics (NEOS) +17%,Aytu BioScience (AYTU) +14%, Vericel (VCEL) +14%, Brickell Biotech (BBI) +14%, Infinity Pharmaceuticals (INFI) +13%.Losers: Translate Bio (TBIO) -32%, ContraFect (CFRX) -13%, Lipocine (LPCN...
Translate Bio (TBIO) -26% after Translate Bio’s Cystic Fibrosis therapy fails to improve lung function in Phase 1/2 trial.PhaseBio Pharmaceuticals (PHAS) -14% on equity raise.Broadway Financial (BYFC) -13% after stockholders of Broadway Financial and CFBan...
Gainers: Takung Art (TKAT) +122%.Zhongchao (ZCMD) +52%.Oriental Culture (OCG) +43%.Integrated Media Technology (IMTE) +43%.Immatics (IMTX) +33%.Puyi (PUYI) +29%.Willis Lease Finance (WLFC) +24%.Lipocine (LPCN) +24%.Liquid Media (YVR) +21%.Sigma Labs (SGLB) +20%.Losers: Sun...
Gainers: Zhongchao (ZCMD) +53%, Immatics (IMTX) +42%, Lipocine (LPCN) +23%, FSD Pharma (HUGE) +18%, Nabriva Therapeutics (NBRV) +18%.Losers: SunLink Health Systems (SSY) -28%, Rubius Therapeutics (RUBY) -17%, CHF Solutions CHFS&...
Lipocine Announces Financial Results For The Year Ended December 31, 2020 PR Newswire SALT LAKE CITY , March 11, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today...
Lipocine To Present At M Vest / Maxim Conference And At The Lytham Partners Conference PR Newswire SALT LAKE CITY , March 11, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine dis...
Lipocine (LPCN) shares rise nearly 6% premarket after announcing the publication of preclinical results supporting the therapeutic potential of LPCN 1144 in the treatment of and non-alcoholic steatohepatitis ("NASH") and hepatic fibrosis.The results were featured in a pape...
Lipocine Announces Publication in Journal of Endocrinological Investigation Highlighting the Potential of LPCN 1144 in the Treatment of NASH and Hepatic Fibrosis PR Newswire SALT LAKE CITY , March 4, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinic...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 02:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study PR Newswire Met standard bioequivalence (BE) criteria C max, AUC 0-t , and AUC 0- ∞ C trough criterion was met LPCN 1154 was well tolerat...
Shares of Lipocine Inc. (NASDAQ: LPCN) traded at a new 52-week high today and are currently trading at $8.96. So far today, approximately 78,318 shares have been exchanged, as compared to an average 30-day volume of 32,701 shares. Lipocine Inc., a clinical-stage biopharmaceutical company, foc...